Nuedexta is indicated for the treatment of pseudobulbar affect (PBA).
Impax has submitted a new drug application (ANDA) containing a paragraph IV certification for a generic version of Nuedexta with the US Food & Drug Administration (FDA).
Once the ANDA is approved by FDA, Global Pharmaceuticals, Impax’s generic division, will commercialize the product.